To the best of our knowledge, there have been no prospective studies on the use of 1G or 2G EGFR-TKIs, followed by sequential treatment including 3G EGFR-TKI and cytotoxic chemotherapy in patients with uncommon EGFR mutation-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.